Two CRUK 野狼社区 Institute Clinician Scientists elected to the Academy of Medical Sciences
The Fellowship of the Academy of Medical Sciences comprises some of the UK鈥檚 leading medical researchers, each of whom has made substantial contributions to advancing patient health and care through research.
Election to the Academy recognises excellence in science, leadership and the translation of research into real-world impact. This year we鈥檙e celebrating two such additions to the Academy - and of the Cancer Research UK 野狼社区 Institute.
The is a part of the University of 野狼社区 core funded by Cancer Research UK. It forms the discovery engine within the 野狼社区 Cancer Research Centre in which world-class, basic, translational and clinical research takes place to save lives from cancer.
Professor Samra Turajli膰
Professor Turajli膰 is Director of the Cancer Research UK 野狼社区 Institute and leader of the Institute鈥檚 group. She has been elected to the Academy for her leadership in cancer medicine and genomics, and spearheading of major national and international research programmes to better understand tumour evolution and improve cancer treatment. These include large-scale studies of renal cancer and multiomic approaches to immunotherapy, all undertaken alongside her work as a clinician at the Royal Marsden and Christie hospitals. Within 野狼社区 she is now steering the future of integrated basic, translational, and clinical research initiatives in the pursuit of fresh innovations to save lives from cancer.
鈥�I share this moving recognition with the extraordinary scientists that have passed through my research groups and my many collaborators without which our work would never have been possible. The rapid advances we're seeing in solutions to cancer are enabled by and depend on a culture of deep collaboration between academics, clinicians, technological specialists and industry. It is in this collaborative cross-disciplinary research both in 野狼社区 and across the many sectors represented in within the Academy of Medical Sciences, where our shared knowledge and expertise can be applied to save lives.鈥�
Professor Tim Somervaille
Professor Somervaille鈥檚 election to the Academy recognises his leadership in blood cancer research and clinical practice as Senior Group Leader at the Cancer Research UK 野狼社区 Institute鈥檚 group, Professor of Haematological Oncology at The University of 野狼社区 and Honorary Consultant Haematologist at The Christie NHS Foundation Trust. His work has advanced understanding of the molecular mechanisms driving myeloid blood cancers and broadened treatment options through a sustained commitment to translating biological discoveries into innovative therapies and clinical trials.
鈥淭his recognition by the Academy of Medical Sciences reflects the extraordinary dedication of everyone who has worked alongside me over the years 鈥� the scientists, clinicians and, above all, the patients who make our research possible and meaningful. I am also deeply grateful to the many members of the public who have supported Cancer Research UK and Blood Cancer UK, whose funding has underpinned my research throughout my career. In 野狼社区, everything we do is ultimately about finding better treatments and improving outcomes for patients, and I have been proud to see my team contribute both to advances in our understanding of leukaemia and myeloproliferative neoplasms, and to the development of new therapeutic approaches. Within the Academy of Medical Sciences, I hope to support a strong culture of collaboration and translation, and to help champion the next generation of researchers who will build on these discoveries in ways we cannot yet imagine.鈥�
Recognition for 野狼社区
This substantial recognition reflects not only Samra and Tim鈥檚 achievements, but also the contributions of Institute staff across research groups, facilities and operational teams. The collaborative environment within the Institute plays an essential role in enabling the research that ultimately benefits patients and makes achievements such as this possible.
The Cancer Research UK 野狼社区 Institute comprises of 14 research groups investigating solutions to an array of cancer challenges, and 11 core facilities in which cutting edge research technologies are being applied to innovate and improve cancer treatments.